摘要
目的探讨骨钙素(osteocalcin,OST)、骨碱性磷酸酶(bone alkaline phosphatase,BAP)对肝癌并骨转移的预测作用及其伊班膦酸钠对骨代谢的影响。方法收集肝癌并骨转移患者16例、肝癌并非骨转移患者22例及肝癌无转移患者20例,并予伊班磷酸钠治疗肝癌并骨转移组,检测各组及肝癌并骨转移治疗前、治疗28、56及84 d骨钙素、骨碱性磷酸酶水平,比较各组间及治疗前后其差异。结果肝癌并骨转移组、肝癌非骨转移组、无转移组血清骨钙素水平分别为31.12±4.18、13.00±6.92、10.23±1.34,骨碱性磷酸酶分别为20.11±1.65、11.41±1.25、10.78±1.35,其中骨转移组骨钙素及骨碱性磷酸酶水平较其他两组差异有统计学意义(P<0.05)。伊班膦酸钠注射液可降低肝癌骨转移组骨钙素及骨碱性磷酸酶水平,治疗后较治疗前差异有统计学意义(P<0.05)。结论骨钙素、骨碱性磷酸酶对肝癌并骨转移患者有较好的预测作用,伊班膦酸钠注射液可有效治疗骨转移瘤,机制可能与降低骨钙素及骨碱性磷酸酶相关。
Objective To investigate the prognosis of OST（osteocalcin）and BAP（bone alkaline phosphatase）for he-patic carcinoma with bone metastases patients and valuation of Ibandronate. Methods 16 patients of hepatic carcinoma with bone metastases,22 patients of hepatic carcinoma without bone metastases and 20 patients of hepatic carcinoma without metastases were collected. The hepatic carcinoma with bone metastases group was treated with Ibandronate. To observe the defferences of BAP and OST in three groups and treatment or not. Results The levels of serum OST in hepatic carcinoma with bone metastases group,hepatic carcinoma without bone metastases group and hepatic carcinoma without metastases group were 31. 12 ± 4. 18,13. 00 ± 6. 92,10. 23 ± 1. 34,respectively;And the levels of BAP in three groups were 20. 11 ± 1. 65,11. 41 ± 1. 25,10. 78 ± 1. 35,respectively. The levels of OST and BAP increased significantly in the bone metastasis group（P 〈 0. 05）. Ibandronate Injection reduced the levels of OST and BAP in hepatic carcinoma with bone metastasis group. Conclusion The value of BAP and OST were significantly higher in hepatic carcinoma with bone metastases pa-tients,which can be used as reference index of clinical prediction. Ibandronate Injection was effective in the treatment of bone metastases and the mechanism may be related to reduce the levers of OST and BAP.
出处
《药学研究》
CAS
2016年第7期422-424,共3页
Journal of Pharmaceutical Research
关键词
肝癌
骨转移
骨钙素
骨碱性磷酸酶
伊班膦酸钠
Hepatic carcinoma
Bone metastasis
Osteocalcin
Bone alkaline phosphatase
Ibandronate
